Item Details

title

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND BONE HEALTH: RESULTS FROM A PILOT RANDOMIZED CONTROLLED TRIAL

author

Dinkla, Lauren

abstract

BACKGROUND: This project’s purpose is to explore the impact of GLP1Ra-based therapy on measures of bone health in older adults. METHODS: Data comes from a 20-week randomized controlled trial (NCT05786521) which enrolled 20 older adults with a BMI ≥27 kg/m2. Participants were allocated to a combination of 1.0 mg/weekly semaglutide + lifestyle counseling (“intervention”; n=10) or lifestyle counseling alone (“control”; n=10). Total body weight, DXA-acquired bone mineral density (BMD), and bone turnover markers (BTM) [C-terminal telopeptide of type 1 collagen (CTX), and procollagen type I N-propeptide (P1NP)] were measured at baseline and 20-weeks. RESULTS: At baseline, participants were 72.7±4.8 years of age, 50% women, 45% Hispanic, and living with obesity (BMI: 32.9±4.0 kg/m2). After 20 weeks, the intervention group experienced greater weight loss than control (-5.3% compared to -0.89%; p=0.006). No significant differences in whole body BMD were reported between the groups, p=0.77. Likewise, no differences in BTM were observed; CTX: p=0.56, P1NP p=0.78. CONCLUSIONS: In this pilot study, 5% weight loss achieved with GLP1Ra use was not associated with significant change in BMD or BTM compared to lifestyle alone, however, CTX and P1NP increased.

subject

bone formation

bone mineral density

bone resorption

glucagon‐like peptide‐1 receptor agonist

older adults

randomized controlled trial

contributor

Beavers, Kristen M (advisor)

Miller, Gary (committee member)

Beavers, Daniel P (committee member)

Cortes, Tiffany (committee member)

date

2025-06-24T08:36:31Z (accessioned)

2025 (issued)

degree

Health and Exercise Science (discipline)

embargo

2027-06-23 (terms)

2027-06-23 (liftdate)

identifier

http://hdl.handle.net/10339/111018 (uri)

language

en (iso)

publisher

Wake Forest University

type

Thesis